Skip to main content

People in the News: Jean Franchi, Paul Ethridge, Laura Sullivan, and more


Good Start Genetics has expanded its senior management team.

Jean Franchi will serve as chief financial officer. Previously, she held a variety of senior positions at Genzyme (now part of Sanofi), including as senior vice president of corporate finance.

Paul Ethridge will be the company's vice president of human resources. He spent the last 20 years at GlaxoSmithKline, most recently as global vice president of human resources for its consumer healthcare supply division.

Laura Sullivan will be vice president of customer care and reimbursement. She previously served as vice president of reimbursement and contracting at Genzyme Genetics (now part of Laboratory Corporation of America).

Good Start has also promoted Gregory Porreca, a founder of the company, to vice president of research and technology, and Stephanie Hallam to vice president of laboratory operations and medical director.

Knome has expanded its management team, hiring Chuck Abdalian as chief financial officer, Adam Rosenberg as senior vice president and head of corporate development, and Jay Therrien as senior vice president and head of global sales.

Abdalian most recently served as senior vice president of finance and chief financial officer of Molecular Insight Pharmaceuticals. He also served as senior vice president of finance and chief financial officer at Coley Pharmaceutical Group, CEO of Pelias Technologies, and chief financial officer of Emisphere Technologies. He holds a BS from Norwich University and an MBA from the Wharton School at the University of Pennsylvania.

Rosenberg, prior to joining Knome, advised emerging companies as a director and consultant and also co-founded the start-up Clean Membranes. He has also served as CEO of Link Medicine and helped launch the law firm Faber Daeufer & Rosenberg PC. He holds a BA from Whittier College and a JD from University of Virginia School of Law.

Thierrien was previously vice president of commercial operations and sequencing at Life Technologies. He has also held various positions at Illumina, including director of sales for Asia Pacific and Japan. He holds a BS from the University of Illinois at Urbana-Champaign and a PhD from the University of Kansas.

Knome has also appointed Hugh Reinhoff to its scientific advisory board. Reinhoff is currently a managing director of Life Science Venture Partners, an adjunct scientist at the Children's Hospital Oakland Research Institute, and CEO of FerroKin BioSciences.

Reinhoff founded the nonprofit, and previously served as CEO and chairman of the board at DNA Sciences. He was also founding director of Healtheon, now known as WebMD Health. He holds an MD from the Johns Hopkins University School of Medicine.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.